Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Wolbachia endosymbionts are intracellular Gram-negative bacteria of the Alphaproteobacteria, closely related to Anaplasma and Rickettsia[1][2]. They are maternally transmitted and infect an estimated 40–66% of insect species, as well as filarial nematodes of medical importance[1][5]. Wolbachia manipulate host reproduction to favor their own transmission, confer resistance to viral pathogens in insects, and are essential for nematode development and fertility[1][2][4][6]. In certain hosts, such as bedbugs, Wolbachia have evolved mutualistic roles by synthesizing vitamins[6]. Targeting Wolbachia with antibiotics is a successful strategy to treat filarial diseases and is being developed for vector-borne disease control[1][2].
Inhibition of bacterial protein synthesis, causing depletion of intracellular Wolbachia. Disruption of nematode development and reproduction through loss of essential cellular functions in the host.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Wolbachia endosymbiont (null).